Athersys (NASDAQ:ATHX) Getting Somewhat Favorable Media Coverage, Analysis Shows

News stories about Athersys (NASDAQ:ATHX) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9713941491008 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several equities research analysts recently commented on the company. ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Athersys in a research report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Athersys currently has an average rating of “Buy” and a consensus price target of $7.08.

Athersys (ATHX) traded up 3.26% on Friday, reaching $2.22. The company had a trading volume of 1,731,320 shares. The stock’s 50 day moving average is $1.72 and its 200-day moving average is $1.52. Athersys has a 1-year low of $1.02 and a 1-year high of $2.30. The stock’s market capitalization is $252.88 million.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. Athersys had a negative return on equity of 91.02% and a negative net margin of 936.77%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) EPS. On average, equities analysts predict that Athersys will post ($0.24) EPS for the current fiscal year.

WARNING: “Athersys (NASDAQ:ATHX) Getting Somewhat Favorable Media Coverage, Analysis Shows” was reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/athersys-athx-receiving-somewhat-favorable-media-coverage-study-shows/1566271.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster


Leave a Reply

 
© 2006-2017 BBNS.